Combined tebentafusp and SBRT showed disease control in a patient with metastatic uveal melanoma.
One Woman’s Rare Eye Cancer Spread. Then a New Combo Stopped It Cold.
This case report describes a 39-year-old woman with localized uveal melanoma who developed liver and hilar adenopathy metastases. She receiv…
This story shows how combining a new immune drug with targeted radiation may help the body fight cancer longer, even after it has spread.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …